Objective: To evaluate the clinical efficacy and impact on pulmonary function of ambroxol hydrochloride combined with antibiotics in the treatment of chronic bronchitis.
Methods: This randomized controlled trial involved the enrollment and randomization of 98 CB patients admitted to Anting Hospital from January 2020 to January 2021, with participants divided into an observation group and a control group at a 1:1 ratio, comprising 49 cases in each group. The control group received cefmetazole alone, whereas the observation group received ambroxol hydrochloride combined with antibiotics. The two groups were compared in terms of time required for mitigation of clinical symptoms, clinical effectiveness, and indicators for pulmonary function.
Results: The observation group showed a reduction in symptom disappearance time by 3.3 days and a 9% higher total effective rate compared to the control group. After treatment, the observation group had elevated FEV1 (22.64%), FVC (31.64%), and FEV1/FVC (9.79%) compared with the control group.
Conclusion: Ambroxol hydrochloride combined antibiotics are effective in the treatment of CB, indicating potential for enhanced quality of life and reduced disease burden for patients with chronic bronchitis.